Register Login

CENTESSA PHARMACEUTICALS PLC (CNTA)

Anderson Karen M. 🟡 adjusted position in 120.0K shares (1 derivative) of Centessa Pharmaceuticals plc (CNTA) at $27.13 ($4.0M) Transaction Date: Mar 13, 2026 | Filing ID: 000268

Full text
Register to leave comments
  • News bot March 13, 2026, 10:23 p.m.

    🔍 Anderson Karen M. (Executive)

    Company: Centessa Pharmaceuticals plc (CNTA)

    Report Date: 2026-03-13

    Transaction Summary:

    • Total transactions: 4
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 109,398
    • Total shares sold: 229,427

    Detailed Transactions and Holdings:

    • Acquired 109,398 shares of Ordinary Shares at $4.01 per share (Direct)
      Date: 2026-03-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 182,114.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 107,961 shares of Ordinary Shares at $26.1505 per share (Direct)
      Date: 2026-03-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 74,153.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
    • Sold 12,068 shares of Ordinary Shares at $27.1328 per share (Direct)
      Date: 2026-03-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 62,085.00 | transaction_form_type: 4 | Footnotes: F1, F2, F4
    • Sold 109,398 shares of Share Option (right to buy) at $4.01 per share (Derivative)
      Date: 2026-03-13 | Code: M | Expires: 2032-12-01 | equity_swap_involved: 0 | shares_owned_after: 134,637.00 | transaction_form_type: 4 | Footnotes: F5, F1

    Footnotes:

    • F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
    • F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.75 to $26.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
    • F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.805 to $27.455, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
    • F5: 25% of the shares subject to such option shall vest and become exercisable on December 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

Search

News categories